医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

BeiGene Announces Addition of Dr. Ronald Levy to Scientific Advisory Board

2014年03月03日 PM10:25
このエントリーをはてなブックマークに追加


 

BEIJING

BeiGene (Beijing), Co., Ltd., an innovative oncology company focused on developing targeted and immune-oncology therapeutics, today announced the addition of Dr. Ronald Levy, M.D., to its Scientific Advisory Board. Dr. Levy is Professor of Medicine, Director of the Lymphoma Program and Former Chief of the Division of Oncology at Stanford University.

“We are delighted to welcome Ron to our SAB, with his in-depth expertise in lymphoma and immune-oncology and his extensive experience in the drug discovery process,” said John V. Oyler, Chief Executive Officer of BeiGene. “Ron has been a pioneer in the field of immunotherapy for lymphoma indications, including research that has helped elucidate the molecular underpinnings of the disease, and his subsequent work on specific drug development makes him a valuable addition to our team of advisors as we work to develop novel therapeutics that can address these areas of high unmet need for patients.”

“BeiGene is a leader in the oncology space with a novel translational research platform and unique patient access that has already produced several exciting targeted and immune-oncology drug candidates,” said Dr. Levy. “I look forward to working with their noteworthy team of scientists and advisors to bring these therapeutics through clinical development and to patients in need of additional treatment options.”

Dr. Levy is a member of the National Academy of Sciences and the Institute of Medicine. He was the first clinician to successfully treat human lymphoma with a monoclonal antibody, and also made important contributions to the development of rituximab (Rituxan®) for the treatment of lymphoma. Dr. Levy has received international acclaim for his work in the field, including the Karnofsky Award from the American Society of Clinical Oncology, the Medal of Honor by the American Cancer Society, the Armand Hammer Award for Cancer Research, the General Motors Charles Kettering Prize, the Damashek Prize from the American Society of Hematology, and the King Faisal International Prize in Medicine.

Dr. Levy joins Drs. Neal Rosen, Charles Sawyers, David Schenkein, Xiaodong Wang and Steve Young on BeiGene’s Scientific Advisory Board.

About BeiGene (Beijing), Co., Ltd.

BeiGene is an innovative Chinese oncology R&D company focused on discovering, developing and commercializing targeted and immune-oncology therapeutics through a novel translational research platform that combines unique access to internal patient-derived biopsies with strong oncology biology. With a team of 150 scientists and staff, its pipeline is comprised of novel oral small molecules and monoclonal antibodies for cancer. BeiGene Ltd. is a Cayman Islands exempted company that is an investor in and collaborator with BeiGene (Beijing), Co. Ltd. For more information, please visit our website at www.beigene.com.

CONTACT

Media/Investors:
BeiGene (Beijing), Co., Ltd.
Jesse
Baumgartner, 212-362-1200
pr@beigene.com

Related Posts Plugin for WordPress, Blogger...
 

同じカテゴリーの記事 

  • ADCセラピューティクスが当社の新規抗体薬物複合体ADCT-402の第I相中間データを発表
  • Vedanta Biosciences Granted Four New U.S. Patents Expanding Coverage for Compositions and Methods of Use for Therapeutics Based on Microbiome-Derived Bacterial Consortia
  • Daiichi Sankyo and Puma Biotechnology Announce Research Collaboration with Major Cancer Center in HER2-Mutated Cancer
  • 武田和Seattle Genetics呈报3期ECHELON-1临床试验的阳性数据,该试验评估ADCETRIS® (brentuximab vedotin)用于晚期霍奇金淋巴瘤的一线治疗
  • ADCセラピューティクスが当社の新規抗体薬物複合体ADCT-301の第I相中間データを発表